Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
adverse drug reaction
apomorphine
aspartate aminotransferase
catechol-o-methyltransferase inhibitor
cost effectiveness
diarrhea
dopamine agonist
drug interactions
dyskinesia
entacapone
enzyme inhibition
enzyme, serum
hepatic failure
heralding manifestation
internet
L-dopa
L-dopa, controlled release
L-dopa, drug interactions with and side effects of
liver disease
liver function enzymes
mortality
neuroleptic malignant syndrome
neurologic disease, diagnoses of
neurologic signs
Parkinson disease
Parkinson disease, diagnosis
Parkinson disease, fluctuations in
Parkinson disease, on-off phenomena in
Parkinson disease, treatment of
Parkinson disease, wearing off
patient information and support
practice guidelines
review article
serum alanine aminotransferase
serum glutamic oxaloacetic transaminase
serum glutamic pyruvic transaminase
sinemet
Stalevo
tolcapone
treatment of neurologic disorder
web sites
Showing articles 0 to 50 of 842 Next >>

Diagnosis and Initial Management of Parkinsons Disease
NEJM 353:1021-1027, Nutt,J.G.&Wooten,G.F., 2005

Two Patients With COMT Inhibitor-Induced Hepatic Dysfunction and UGT1A9 Genetic Polymorphism
Neurol 65:1820-1822, Martignoni,E.,et al, 2005

Stalevo for Parkinson's Disease
The Medical Letter 46:39, , 2004

Comtan (Entacapone) The Treatment of Parkinson's Disease, Questions & Answers
APDA Ed Suppl #15, Watts,R.L., 2001

The Catechol-O-Methyltransferase (COMT) Inhibitor Entacapone Enhances the Pharmacokinetic and Clinical Response to Sinemet CR in Parkinson's Disease
JNNP 68:589-594, Piccinni,P.,et al, 2000

Tolcapone and Hepatotoxic Effects
Arch Neurol 57:263-267, Olanow,C.W.&Tasmar Advisory Panel, 2000

Tasmar (tolcapone) Labeling Revisions of Package Insert
Roche Laboratories, , 1998

Tolcapone for Parkinson's Disease
The Medical Letter 40:60-61, , 1998

Random, Placebo-Contr Study of Tolcapone in Pts with Fluctuating Parkinson Dis Trtd With Levodopa-Carbidopa
Arch Neurol 55:1089-1095, Adler,C.H.,et al, 1998

Catechol-O-Methyltransferase Inhibitors for Treatment of Parkinson's Disease
Lancet 351:1221-1222, Nutt,J.G., 1998

Tolcapone in Stable Parkinson's Disease:Efficacy and Safety of Long-Term Treatment
Neurol 49:665-671, Waters,C.H.,et al, 1997

COMT Inhibition with Tolcapone Reduces the"Wearing Off"Phenomenon & Levodopa Requirements in Fluctuating Parkinsonisn Pts
JNNP 63:421-428, Baas,H.,et al, 1997

Tolcapone Improves Motor Function in Parkinsonian Pts with the"Wearing Off"Phenomenon
Neurol 49:1066-1071, Rajput,A.H.,et al, 1997

Entacapone Improves Motor Fluctuations in Levodopa-Treated Parkinson's Dis Pts
Parkinson Study Group, Ann Neurol 42:747-7551997., , 1997

Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024

Diagnosis and Management of ANCA-Associated Vasculitis
Lancet 403:683-698, Kronbichler, A., et al, 2024

Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients with Atrial Cardiopathy, The ARCADIA Randomized Clinical Trial
JAMA 331:573-581, Kamel,H.,et al, 2024

Repurposing Erectile Dysfunction Medication for Alzheimer Disease Prevention
Neurol 102:e209180, Yasara,S., & Nidadavolu,L., 2024

Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023

Intravenous Thrombolysis in Patients with Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants
JAMA Neurol 80:233-243, 231, Meinel,T.R.,et al, 2023

Progressive Hemiparesis and White Matter Abnormalities in an HIV-Negative Patient
Neurol 100:1156-1163, Jabbari,E.,et al, 2023

Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023

Perioperative Management of Anticoagulant and Antiplatelet Therapy
NEJM Evid doi:10.1056/EVIDna2200322, Douketis,J.D. & Spyropoulos,A.C., 2023

Polymyalgia Rheumatica
Lancet 402:1459-1472, Espigol-Frigole,G.,et al, 2023

Severe Amyloid-Related Imaging Abnormalities After Anti-B-Amyloid Monoclonal Antibody Treatment
Neurol 101:1079-1080, Bonami,S.,et al, 2023

Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors in Patients with Melanoma
Neurol 101:e2472-e2482, Pepys,J.,et al, 2023

Clinicopathologic Conference, Encephalitis due to Behcets Disease
NEJM 387:925-933, Case 27-2022, 2022

In Patients with Melanoma Brain Metastases, is Combination Immune Checkpoint Inhibition a Safe and Effective First-Line Treatment? A Critically Appraised Topic
Neurologist 27:290-297, Gritsch, D.,et al, 2022

Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory
Neurol 98:486-498, Turan, T.N.,et al, 2022

Idiopathic Intracranial Hypertension (Pseudotumor Cerebri): Prognosis and Treatment
www.UptoDate.com Mar, Wall, M. & Lee, A.G., 2022

Recent Advances in the Diagnosis and Management of Cluster Headache
BMJ 376:e059577, Schindler, E. & Burish, M.J., 2022

Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects
JENDSO 6:1-7, Hamidi, S.,et al, 2022

Atypical Posterior Reversible Encephalopathy Syndrome Associated with Lenvatinib Therapy in a Patient with Metastatic Thyroid-Cancer
Cancer Reports doi:10.1002/cnr2.1605, Abhishek, M.,et al, 2022

A 48-Year-Old Woman with 6 Months of Vivid Visual Hallucinations
Neurol 99:166-171, Kizza, J.,et al, 2022

Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022

Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary
Neurol 98:31-43, Price, R.,et al, 2022

Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation
Ann Neurol 91:78-88, Polymeris, A.A.,et al, 2022

Confused About Confusion
NEJM 386:80-87, Spanjaart, A.M.,et al, 2022

Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors
Neurol 97:e191-e202, Nersesjan, V.,et al, 2021

Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021

Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021

Stroke Prevention by Anticoagulants in Daily Practice Depending on Atrial Fibrillation Pattern and Clinical Risk Factors
Stroke 52:3121-3131, Grimaldi-Bensouda, L.,et al, 2021

Clinical Outcomes in Atrial Fibrillation Patients with a History of Cancer Treated with Non-Vitamin K Antagonist Oral Anticoagulants
Stroke 52:3132-3141, Chan, Y.H.,et al, 2021

Left Ventricular Dysfunction Among Patients with Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin
JAMA Neurol 78:1454-1460, Merkler, A.E.,et al, 2021

Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021

Cranial Nerve Disorders Associated with Immune Checkpoint Inhibitors
Neurol 96:e866-e875, Vogrig, A.,et al, 2021

Economic Evaluation of Andexanet Versus Prothrombin Complex Concentrate for Reversal of Factor Xa-Associated Intracranial Hemorrhage
Stroke 52:1390-1397, Micieli, A.,et al, 2021

The Effects of Long-Term Medication Use in Alzheimer Disease
Neurol 96:e2247-e2250, Karceski, S., 2021

Administering Thrombolysis for Acute Ischemic Stroke in Patients Taking Direct Oral Anticoagulants
JAMA Neurol 78:515-518, Seiffge, D.J.,et al, 2021



Showing articles 0 to 50 of 842 Next >>